Patents
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
02/2013
02/27/2013CN102947336A Methods of treating diabetes with dll4 antagonists
02/27/2013CN102947335A Anti-polyubiquitin antibodies and methods of use
02/27/2013CN102947334A Antibodies for treatment of clostridium difficile-associated infection and disease
02/27/2013CN102947333A 抗体组合物 Antibody composition
02/27/2013CN102946906A Production of heteromultimeric proteins
02/27/2013CN102946905A Cgrp antibodies
02/27/2013CN102946904A Arthritis treatment
02/27/2013CN102946903A High concentration antibody formulations
02/27/2013CN102946902A Bispecific antibodies
02/27/2013CN102946901A Conjugates utilizing platform technology for stimulating immune response
02/27/2013CN102946900A Vaccines for pandemic influenza
02/27/2013CN102946899A Pharmaceutical composition
02/27/2013CN102946867A Compoisitons comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists
02/27/2013CN102946861A Concentrated protein formulations and uses thereof
02/27/2013CN102943087A Novel subunit vaccine against rabbit hemorrhagic disease virus and preparation method thereof
02/27/2013CN102942631A Humanized anti-cmet antagonists
02/27/2013CN102942629A Humanized antibody for resisting severe fever with thrombocytopenia syndrome bunyavirus (SFTSV)
02/27/2013CN102942614A Preparation method and application of high-purity polysaccharopeptide
02/27/2013CN102940886A Biological barrier penetrating agent and preparation method thereof
02/27/2013CN102940883A Therapeutic composition to improve the effect of the therapy with anti-epidermal growth factor receptor antibodies
02/27/2013CN102940875A Paa protein, antibody prepared from the same, and application thereof
02/27/2013CN102268410B Newcastle disease virus heat-resistant attenuated strain adapted to baby hamster kidney passage cell and preparation method and application thereof
02/27/2013CN102250843B Genetic engineering marked attenuated vaccine strain of porcine reproductive and respiratory syndrome virus and application thereof
02/27/2013CN102247600B Method for preparing diluent for pseudorabies live vaccine
02/27/2013CN102154219B Swine influenza A H1N1 virus and use thereof
02/27/2013CN101947323B Gram negative bacterium vaccine and preparation method thereof
02/27/2013CN101613398B Surface lipoprotein of streptococcus suis type-2, preparation method thereof and application
02/27/2013CN101463084B Gene engineering monoclonal antibody combined with A-beta oligomer specificity
02/27/2013CN101220370B Bifidobacteria-bacillus coli shuttle expression vector, preparation method and application thereof
02/26/2013US8383806 Method of reversing carboplatin resistance by inhibition of HGFIN
02/26/2013US8383802 Nucleic acids encoding antibodies that bind factor D
02/26/2013US8383790 Modified surface antigen
02/26/2013US8383788 For therapy of cancer or tumorous growth
02/26/2013US8383781 Anti-NIK antibodies and uses thereof
02/26/2013US8383780 Antibodies to TGFβ
02/26/2013US8383777 13-transmembrane protein expressed in prostate cancer
02/26/2013US8383775 Cytokine zalpha11 ligand
02/26/2013US8383769 Peptides for inhibiting chemokine binding to chemokine receptors
02/26/2013US8383767 Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
02/26/2013US8383371 Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein
02/26/2013US8383358 Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy
02/26/2013US8383354 Diagnostic method for atherosclerosis
02/26/2013US8383153 Poly(amidoamine) oligomer hydrogel for drug delivery and drug carrier using the same
02/26/2013US8383133 Conjugates of Plasmodium falciparum surface proteins as malaria vaccines
02/26/2013US8383132 Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
02/26/2013US8383131 Porcine reproductive and respiratory syndrome isolates and methods of use
02/26/2013US8383129 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability
02/26/2013US8383126 Bacterial pheromones and uses thereof
02/26/2013US8383125 Antimicrobial protein
02/26/2013US8383124 Mobilization of hematopoietic stem cells
02/26/2013US8383123 Method of treatment targeting HEPSIN
02/26/2013US8383122 Process for preparing purified drug conjugates
02/26/2013US8383121 Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
02/26/2013US8383120 Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate
02/26/2013US8383119 Biological substance nesfatin and its related substances and uses thereof
02/26/2013US8383118 Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
02/26/2013US8383117 CD44E tumor specific antibody
02/26/2013US8383116 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
02/26/2013US8383115 Engineered scFv against bovine herpes virus type I
02/26/2013US8383113 Anti-ADDL antibodies and uses thereof
02/26/2013US8383112 Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
02/26/2013US8383111 Inotropic antibodies and therapeutic uses thereof
02/26/2013US8383110 Modulators of Candida hyphal morphogenesis and uses thereof
02/26/2013US8383109 Optimized Fc variants and methods for their generation
02/26/2013US8383108 Therapeutic uses of monoclonal antibodies to the angiotensin-II type 1 receptor
02/26/2013US8383107 Single domain brain-targeting antibody fragments derived from llama antibodies
02/26/2013US8383106 Materials and methods for improved immunoglycoproteins
02/26/2013US8383100 Method to treat and prevent skin diseases with Porifera-based therapeutic compositions treating and preventing skin diseases
02/26/2013US8383096 Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
02/26/2013US8383084 Modify surface of spore to increase adherence to phagocyte; activate phagocytic cells; ingest spore with phagocyte; killing spore by blocking spore-induced phagocyte cell death; increase activation, production of antimicrobial and cytocidal agents endogenous nitric oxide, inflammatory cytokines
02/26/2013US8383081 Anti-CD74 immunoconjugates and methods of use
02/26/2013CA2674885C Anti-ige vaccines
02/26/2013CA2674837C Anti-ige vaccines
02/26/2013CA2524399C Optimized fc variants and methods for their generation
02/26/2013CA2509973C Multi-antigenic alphavirus replicon particles and methods
02/26/2013CA2493406C Gm-negative ehv-mutants without heterologous elements
02/26/2013CA2492068C Assays for assembly of ebola virus nucleocapsids
02/26/2013CA2430115C Recombinant rsv virus expression systems and vaccines
02/26/2013CA2389644C A novel polypeptide hormone phosphatonin
02/26/2013CA2327586C Fap.alpha.-specific antibody with improved producibility
02/25/2013CA2750419A1 Novel treatment, prevention or diagnosis of health problems
02/21/2013WO2013026054A2 Production of infectious rna viruses in yeast
02/21/2013WO2013026004A2 Antibodies that bind integrin alpha-v beta-8
02/21/2013WO2013025936A1 Detection and treatment of metastatic disease
02/21/2013WO2013025925A1 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
02/21/2013WO2013025853A1 Neuregulin antibodies and uses thereof
02/21/2013WO2013025834A2 Compositions and methods related to antibodies to staphylococcal protein a
02/21/2013WO2013025817A1 Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
02/21/2013WO2013025545A2 Drug delivery systems and method of reducing foal infection by treating mares with gallium salts
02/21/2013WO2013025538A2 Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
02/21/2013WO2013025479A1 Jaml specific binding agents, antibodies, and uses related thereto
02/21/2013WO2013025467A2 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow
02/21/2013WO2013025446A2 Anti-fzd10 monoclonal antibodies and methods for their use
02/21/2013WO2013024905A1 Combination drug of antibody against lipopolysaccharide of pseudomonas aeruginosa and antibacterial agent
02/21/2013WO2013024859A1 Molecular mimic mucosal aids vaccine
02/21/2013WO2013024289A1 Livestock improvement
02/21/2013WO2013024157A2 Combinations of host targeting agents for the treatment and the prevention of hcv infection
02/21/2013WO2013024156A2 Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
02/21/2013WO2013024155A1 Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
02/21/2013WO2013024113A1 Influenza h5 vaccines